Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $18.48, but opened at $19.02. Septerna shares last traded at $17.73, with a volume of 12,754 shares traded.
Analyst Upgrades and Downgrades
SEPN has been the subject of several research reports. JPMorgan Chase & Co. assumed coverage on Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 target price for the company. Cantor Fitzgerald began coverage on Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 price objective for the company. Wells Fargo & Company started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $43.00 target price on the stock. Finally, TD Cowen started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a "buy" rating for the company.
Check Out Our Latest Research Report on Septerna
Septerna Stock Down 12.6 %
The business has a fifty day moving average price of $22.18.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Septerna stock. SG Americas Securities LLC bought a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 8,095 shares of the company's stock, valued at approximately $185,000.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Stories
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
